Löschung

 

auch in D richtig Volumen reinkommt und der Kurs über 1 EUR geht. 50 cent bis Jahresende wären auch schon OK.  

Healthsonix durchbrochen.Den Kurs noch ein wenig höher und ich fahre wieder mit gutem Plus daher.:-)  

der Produktion des enSonix@home Gerätes 2.Generation und auf die Infomercials dazu, das wird einen Schub geben.

Richtig los geht es allerdings erst, wenn der erste Finanzbericht rauskommt, je länger man damit wartet, umso mehr Umsatz kann natürlich mit einbezogen werden....

Ich freue mich über weitere billige shares, wie diese Woche, denn es kann durchaus wieder schnell absacken - solange HSXI in den Pinksheets notiert.  

ich glauge zu sagen dass der Kurs spätestens nächste Woche bereits bei min. 25 Cent stehen sollte.Alle warten auf Ahnungsscheine und das spiegelt sich bereits jetzt schon im Kurs wieder.Also ,die 0,25 werden bald geknackt sein ,so meine Vermutung.  

ich persönlich ließ die Hoffnung fahren, das es bis zu der Veröffentlichung der Geschäftszahlen nachhaltig nach oben geht.
Heißt aber nur, das ich meine Haltezeiten der Shares erhöhe und nicht, da ich Scheine abgeben werde.
Einmal kommt die Selbstdartellung über Cristian Radio von Döderlein und der Schein zieht innerhalb 2 Wochen um 1500% an und fällt dann wie ein bleierner Stein nach unten. Nun zieht die Marktwire Veröffentlichung (nicht einmal News) den Kurs an einem Tag von 0,13 auf 0,28 um dann wieder bei Boden 0,20 zu pendeln.
Nun sind wir doch alle darauf eingestellt billig einzusammeln. Zu Brief (über pari) USA nimmt doch keiner mehr was mit.
Einen Run wie bei den 0,45 seh ich nicht noch einmal vor Veröffentlichung der Geschäftszahlen am Jahresende. Aber ich als gebranntes Kind, scheue da eh das Feuer.
Bin einmal in die Bullenfalle getappt.
Bei 0,34 USD zu 0,21 EUR kaufen zu können, sah ich als tolle Sache an. Nochmal lauf ich nicht mehr ins offene Messer.
Gruss
RPM
 

hab's mir dreimal gaaanz langsam durchgelesen und sag' mal ja dazu.
Hinzufügend sei noch was zur Charttechnik gesagt.Sieht identisch zu der Entwicklung wie April diesen Jahres aus.Also wenn einer mich fragt wo denn die nächste Bullen getrieben werden ,dann hier ,buran  

dass M.Ivezic am Freitag von einer Geschäftsreise nach Europa und dem Nahen Osten  zurückgekommen ist, vielleicht gibt es bald wieder News.....

Habe aber nichts gegen einen vorläufigen weiteren Kursverfall, kaufe gerne noch mehr billige Aktien, hehehe.

 

Das ist ja mehr an den Deutschen Börsen als die ganze letzte Woche.
Jetzt geht sie aber ab wie Schmidts Katze. *lol*  

Klassenziel verfehlt, mein Kursziel war 0,50 USD bis Jahresende, wird wohl nix draus :-(.

Keine PR seit dem 31.10.07, der angekündigte Start von Infomercials und Produktion des Gen2 Modells ist ausgeblieben. Die Firma hat sich jetzt in einer eMail an die Shareholder gemeldet, wer den Text noch nicht kennt:

**************************

Here's an update sent out to known HSXI shareholders from Investor Relations at Health Sonix. Looking good for 2008.

Many shareholders have been calling/sending emails wondering why there has been no news for HSXI. I can assure you that management continues to move forward on many fronts, and we look forward to a break out year in 2008. The following captures the essence of most of your enquiries and provides answers:

1. The enSonix@home device has been undergoing QC testing for efficacy, overall performance and durability over the past 3 months and has now been cleared on the main functions for production. Engineering had suggested additional, minor improvements in some of the features and these have been incorporated. Finished production units are expected in February 2008.

2. The infomercial for the enSonix@home unit is essentially complete: the product beauty shots will be completed upon receipt of the finished enSonix@home device.

3. Marketing has recommended that the launch of the infomercial be delayed until February 2008 as the television clutter at this time of year would make it more challenging.

4. Management has scheduled additional meetings in Dubai to address the high level of interest in our products for distribution in the Middle East.

5. The IR meetings in New York have been progressing and 3rd round meetings have been scheduled for next week. HealthSonix expects to announce the selection of one or two institutions to work with the company on its financial planning and application to move to a more senior exchange within the next 2 weeks.

6. The ZingiberRx sampling program has yielded excellent results and several retail listing test markets are underway. A dedicated web site for the cream is almost complete and will go live within 10 days.

7. We are currently concentrating on the ZingiberRx cream and the take home unit as they offer the most immediate sales and profits; however, the AquaSonix and Treatment Centers are still very much part of our long range planning.

Trust the above addresses most of your inquiries, and we thank you for your continued support.  

dass hier im September die Hölle los sein sollte.Und?Wir schreiben mittlerweile Dezember.  

jetzt können wir nur hoffen, dass es mit dem Februar klappt, denn es hängt viel von dem Verkaufsstart des enSonix Gen2 Modell ab. Das ist kurz/mittelfristig der grösste Umsatzbringer.

Die Zingiber-Creme scheint gut zu laufen und der Antrag auf einen Segmentwechsel wird jetzt auch in Angriff genommen. Dazu müsste es auch irgendwann Zahlen geben, dann werden wir sehen, was geht.  

http://www.zingiberrx.com/index.html  

mein Siegerdepot notiert derzeit -60%  

 

schreib nicht so viel Quark. Bestell dir lieber Mal so ein enSonix Gerät oder die ZingiberRx Salbe. Das hilft bei Schmerzen.

Also da hat einer seine 9K zu 0,045 geschmissen. Der Kurs wird aber in USA gemacht und hält sich noch.

Es wird bald wieder gute News geben, dann erholt sich der Kurs auch wieder.  

könnte langsam überwunden sein, heute bei überdurchschnittlichem Volumen ein schönes Plus in USA. Könnte auf baldige News hindeuten.....  

HealthSonix Launches www.ZingiberRx.com to Increase Online Presence
Tuesday February 5, 8:00 am ET


IRVINE, Calif.--(BUSINESS WIRE)--HealthSonix, Inc. (OTC:HSXI)(FWB:H7S) today announced that it has launched a dedicated web site for its ZingiberRx Joint and Muscle cream: www.ZingiberRx.com

ZingiberRx joint and muscle cream is fast acting, non-staining, fast absorbing, and deep penetrating. Unlike most over-the-counter topical ointments, ZingiberRx is not a counter-irritant and does not create a hot or a cold sensation when applied.

Medical research studies into the medicinal properties of various plants in the ginger (Zingiberaceae) family have isolated the Zingiber cassumunar and Zingiber officinale species for their anti-inflammatory, anti-allergic and pain relieving properties.

“The launch of this web site coincides with on going retail sampling and couponing programs being tested in major pharmacy chains.” said Dieter Doederlein, Vice President Corporate Development of HealthSonix. “The response to this new pain relieving cream, the first of its kind with ginger, continues to be very positive. We continue being a best selling topical pain reliever at those locations. “

The Company is also launching a major online sales and marketing campaign with Google and Yahoo adwords and banner ads on websites that cater to the 50+ population segment: “This new marketing program has been designed to increase awareness and promote direct to consumer sales from our online store.” added Doederlein.

HealthSonix, Inc. (OTC:HSXI - News)(FWB:H7S) is a publicly traded research oriented medical technology company that develops and markets medical devices and healthcare products for institutional and consumer use. The company’s patent pending medical devices deliver sound pressure waves to the human body for relief of pain and other musculoskeletal conditions. The focus is on arthritis, athletic injuries and conditions where acute or chronic pain is the cardinal symptom.

More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.

Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.



Contact:
for HealthSonix, Inc.
Dieter Doederlein, 1-877-622-2121 x112

--------------------------------------------------
Source: HealthSonix, Inc.  

IRVINE, Calif.--(BUSINESS WIRE)--HealthSonix Inc. (OTC:HSXI) (FRANKFURT:H7S) today announced that it is has approved the final sample of its second generation enSonix medical device. Shipments of finished product are expected to commence in the second quarter.


The enSonix personal treatment device has been registered and cleared with the United States, Food and Drug Administration (FDA), and has been designated as a class1 device, the safest classification for medical devices. It has been indicated for pain reduction and muscle relaxation.

“With this new medical device, we offer our customers affordable, effective arthritis pain relief without side effects. Patients can use it in the comfort of their own homes. The enSonix therapy is especially effective when used in combination with the most popular pain relievers. There is an incremental therapeutic benefit when you combine therapies,” said Dieter Doederlein, Vice President of Corporate Development. “Arthritis is still the number one cause of chronic pain in North America and the HealthSonix breakthrough medical technology is very timely as the population segment most susceptible to arthritis will double over the next 20 years.”

The sound pressure waves generated by the enSonix medical device are believed to work in three ways: they stimulate mechanoreceptors in the skin, which in turn communicate with the brain and block pain messages from getting through (gate control theory of pain); they create an exercise effect in the muscles, which encourages the production and release of endorphins, the body's natural pain killers; and increase in blood circulation.

“Our objective is very clear; deliver as much product this year as we can to fulfill significant order back log that has been created over the past 12 months and to focus on development and expansion of distribution and sales channels for all of our consumer products,” added Mr. Doederlein.

HealthSonix, Inc. (OTC:HSXI)(FWB:H7S) is a publicly traded research oriented medical technology company that develops and markets medical devices and healthcare products for institutional and consumer use. The company’s patent pending medical devices deliver sound pressure waves to the human body for relief of pain and other musculoskeletal conditions. The focus is on arthritis, athletic injuries and conditions where acute or chronic pain is the cardinal symptom.

More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.  

 

 

HealthSonix Gives Green Light for Production of the enSonix Medical Device

16:40 11.02.08  



IRVINE, Calif.--(BUSINESS WIRE)--
HealthSonix Inc. (OTC:HSXI) (FRANKFURT:H7S) today announced that it is has approved the final sample of its second generation enSonix medical device. Shipments of finished product are expected to commence in the second quarter.

The enSonix personal treatment device has been registered and cleared with the United States, Food and Drug Administration (FDA), and has been designated as a class1 device, the safest classification for medical devices. It has been indicated for pain reduction and muscle relaxation.

With this new medical device, we offer our customers affordable, effective arthritis pain relief without side effects. Patients can use it in the comfort of their own homes. The enSonix therapy is especially effective when used in combination with the most popular pain relievers. There is an incremental therapeutic benefit when you combine therapies, said Dieter Doederlein, Vice President of Corporate Development. Arthritis is still the number one cause of chronic pain in North America and the HealthSonix breakthrough medical technology is very timely as the population segment most susceptible to arthritis will double over the next 20 years.

The sound pressure waves generated by the enSonix medical device are believed to work in three ways: they stimulate mechanoreceptors in the skin, which in turn communicate with the brain and block pain messages from getting through (gate control theory of pain); they create an exercise effect in the muscles, which encourages the production and release of endorphins, the body's natural pain killers; and increase in blood circulation.

Our objective is very clear; deliver as much product this year as we can to fulfill significant order back log that has been created over the past 12 months and to focus on development and expansion of distribution and sales channels for all of our consumer products, added Mr. Doederlein.

HealthSonix, Inc. (OTC:HSXI)(FWB:H7S) is a publicly traded research oriented medical technology company that develops and markets medical devices and healthcare products for institutional and consumer use. The companys patent pending medical devices deliver sound pressure waves to the human body for relief of pain and other musculoskeletal conditions. The focus is on arthritis, athletic injuries and conditions where acute or chronic pain is the cardinal symptom.

More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.

Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.


(c)2007 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein
 

das wird wohl bis zum 1. Finanzbericht dauern, wann der genau vorgelegt wird, weiss noch keiner.

@bafin: ich weiss nicht, was du willst, aber ZingiberRX Salbe hat mit Zink nichts zu tun. Ansonsten halte dich mit deinen albernen Sprüchen hier raus. Zur Sicherheit kommst du auf Ignore, ist ja mein Thread und du kannst mit deinesgleichen spielen, falls es noch mehr ID's auf diesem Niveau gibt - hehehe.  

HealthSonix Announces ZingiberRx Joint and Muscle Cream Marketing Program Soaring
Wednesday February 27, 11:14 am ET


IRVINE, Calif.--(BUSINESS WIRE)--HealthSonix, Inc. (OTC:HSXI)(FWB:H7S) today announced that the multi-faceted marketing program for ZingiberRx Joint and Muscle Cream launched earlier this month is hitting stride and exceeding company expectations. The program consisted of launching the website, sampling, direct to consumer sales, test markets in retail stores, and advertising on Google search engines.

“Yesterday alone, we had over 5,300 visits to our website and received over 5,000 requests for samples,“ said Dieter D. Doederlein, Vice President of Corporate Development for HealthSonix. “This is significant because early evidence suggests that we have a high conversion rate from sample to purchase, and we continue to get positive feedback from users of all ages.”

“In addition to the direct to consumer marketing efforts, we have been test marketing the product in regional drug stores and have now progressed to Vendor status with one of the largest national drug store chains in Canada. ZingiberRx is actually the number one selling topical pain reliever in many of the early test locations and we have the full support and participation of the pharmacists when it comes to explaining the product and its benefits,” added Doederlein.

“The response to this new pain relieving cream, the first of its kind with ginger, is just short of amazing. It is really rewarding to witness the instant acceptance of ZingiberRx for the relief of pain and inflammation.”

ZingiberRx joint and muscle cream is fast acting, non-staining, fast absorbing, and deep penetrating. Unlike most over-the-counter topical ointments, ZingiberRx is not a counter-irritant and does not create a hot or a cold sensation when applied.

Medical research studies into the medicinal properties of various plants in the ginger (Zingiberaceae) family have isolated the Zingiber cassumunar species for its anti-inflammatory, anti-allergic and pain relieving properties.

HealthSonix, Inc. (OTC:HSXI)(FWB:H7S) is a publicly traded research oriented medical technology company that develops and markets medical devices and healthcare products for institutional and consumer use. The company’s patent pending medical devices deliver sound pressure waves to the human body for relief of pain and other musculoskeletal conditions. The focus is on arthritis, athletic injuries and conditions where acute or chronic pain is the cardinal symptom.

More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.

Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.



Contact:
HealthSonix, Inc.
Dieter D. Doederlein, 905-212-7711  

HealthSonix to Conduct Clinical Trials with ZingiberRx for Complex Regional Pain Syndrome (CRPS)
Wednesday March 12, 9:43 am ET


IRVINE, Calif.--(BUSINESS WIRE)--HealthSonix, Inc. (OTC:HSXI)(FWB:H7S) today announced that it has strong evidence that ZingiberRx Joint and Muscle Cream with ginger oil can provide pain relief for people with Complex Regional Pain Syndrome (CRPS), also referred to as Reflex Sympathetic Dystrophy (RSD).

The main symptom of CRPS is intense chronic pain, often described as ‘burning’ pain. Additional signs and symptoms include localized swelling; changes in skin temperature and color; joint stiffness; muscle spasms, weakness and loss (atrophy); and decreased range of motion.

“We have been testing ZingiberRx with a CRPS group and the on-going positive feedback we get from the participants has led to the decision to conduct a formal scientific study for this condition,” said Dieter D. Doederlein, Vice President Corporate Development for HealthSonix.

“Members of our St Catharines CRPS support group had excellent outcomes from the ZingiberRx samples you provided. You definitely should consider a clinical trial,” said Helen Small, President of PARC, a national support group that is Promoting Awareness of RSD and CRPS in Canada.

“According to the Mayo Clinic, many cases of complex regional pain syndrome occur after a forceful trauma to an arm or a leg, as a result of motor vehicle accidents, shrapnel blasts and other traumas - such as surgery, heart attacks, infections, fractures and sprained ankles. This could open up a whole new market for ZingiberRx,” added Doederlein.

HealthSonix, Inc. (OTC: HSXI)(FWB: H7S) is a publicly traded research oriented medical technology company that develops and markets medical devices and healthcare products for institutional and consumer use. The company’s patent pending medical devices deliver sound pressure waves to the human body for relief of pain and other musculoskeletal conditions. The focus is on arthritis, athletic injuries and conditions where acute or chronic pain is the cardinal symptom.

More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.

Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.



Contact:
HealthSonix, Inc.
Dieter Doederlein, 877-622-2121

--------------------------------------------------
Source: HealthSonix, Inc.  

die SEC hat einen Verdacht auf Unregelmässigkeiten bei der Mantelübernahme von 26 OTC-Firmen. Das hat nichts mit dem Geschäftsbetrieb von HSXI ansich zu tun. Wer und was im Falle HSXI gelaufen ist, werden wir sehen.

Jedenfalls wurde ich in 2 Fällen von OTC Firmen mein Geld los, dort hatten die Manager ganz klar falsche PR's ausgegeben und einige US-Investoren sogar die SEC informiert. Da ist nichts passiert, obwohl da manipuliert wurde.

HSXI hat Produkte entwickelt und diese kann man kaufen, die sind sogar sehr wirksam, habe ich selber getestet. Betrüger machen so etwas nicht, die wollen nur Aktien verkaufen, solange es geht. Die SEC will sich nur profilieren in dem ganzen Finanzchaos der US-Banken.